Theriva’s Phase 2b VIRAGE trial in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) reported improvements in overall survival, progression-free survival, and duration of response when VCN-01 was added to gemcitabine/nab-paclitaxel versus chemotherapy alone. The signal strengthened in patients who received two doses of VCN-01 spaced three months apart, suggesting a dose- and schedule-dependent effect worth formalizing in a pivotal setting.
The core development is regulatory. EMA’s CHMP issued Scientific Advice endorsing Theriva’s proposed Phase 3 design: a single, double-blind, randomized, placebo-controlled study using overall survival as the primary endpoint with secondary measures including PFS, duration of response, and patient-reported outcomes. Importantly, CHMP aligned on an adaptive design and on repeated “macrocycle” dosing of VCN-01 with standard chemotherapy—explicitly acknowledging the Phase 2b survival signal seen with two doses and allowing for more than two administrations, with openness to even more frequent dosing. CHMP also indicated that, if the study demonstrates a compelling benefit–risk profile, one high-quality Phase 3 could support an EU marketing application. Theriva plans an End-of-Phase 2 meeting with FDA in the first half of 2026 and reports cash runway into Q1 2027 to complete regulatory interactions and advance partnering for manufacturing scale-up and pivotal execution. VCN-01 holds Orphan designation in the EU and US and Fast Track in the US for PDAC, with Rare Pediatric Disease designation in retinoblastoma.
Strategically, the company is pursuing a capital-efficient, single pivotal pathway anchored in a conventional first-line backbone where real-world uptake remains high despite regional variation with modified FOLFIRINOX. The macrocycle strategy is a clear attempt to institutionalize the Phase 2b dosing effect, but it also tests the practical ceiling for systemic oncolytic adenovirus re-dosing in a frail population where immunogenicity, viral shedding management, and cumulative toxicity could challenge continuity of therapy. The adaptive design adds flexibility for sample size and potential timeline optimization, but also elevates operational complexity and demands crisp global alignment between EMA and FDA on interim looks and adaptation rules.
For sites, the implications are nontrivial. Running a blinded, placebo-controlled trial with a systemically administered oncolytic virus will require biosafety SOPs, viral handling and storage protocols, staff training for exposure control, and monitoring for neutralizing antibodies and shedding, all layered atop the chemotherapy regimen. Repeated macrocycles extend scheduling demands and increase the risk of attrition in rapidly progressive PDAC, putting a premium on tight visit coordination and robust patient support. CROs will need mature adaptive trial infrastructure, vigilant DMC operations, and logistics for matched placebo and vector supply. Sponsors and manufacturing partners must deliver consistent GMP-grade adenoviral product at scale with reliable cold-chain and fill–finish, while ensuring lot comparability across adaptations and geographies. Regulators appear willing to consider a single pivotal if the effect size on OS is clear, but will scrutinize durability, safety with repeat dosing, and PROs given the disease’s symptomatic burden.
The next inflection is FDA’s End-of-Phase 2 feedback, which will clarify whether a single multinational Phase 3 is tenable, how frequently VCN-01 can be dosed, and what stratification and interim analyses will govern adaptations. Watch for final comparator choices across regions, the handling of patients eligible for modified FOLFIRINOX, and plans to monitor and mitigate anti-adenoviral immunity over multiple cycles. Funding beyond Q1 2027, manufacturing partnerships, and alignment on adaptive features between EMA and FDA will determine execution risk. In parallel, any guidance on the retinoblastoma program will signal how broadly Theriva intends to deploy its platform and whether pediatric infrastructure can be mobilized without diluting PDAC focus.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
